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Summary
Background DNA methylation profiles associated with childhood asthma might provide novel insights into disease 
pathogenesis. We did an epigenome-wide association study to assess methylation profiles associated with 
childhood asthma. 
Methods We did a large-scale epigenome-wide association study (EWAS) within the Mechanisms of the Development 
of ALLergy (MeDALL) project. We examined epigenome-wide methylation using Illumina Infinium Human 
Methylation450 BeadChips (450K) in whole blood in 207 children with asthma and 610 controls at age 4–5 years, and 
185 children with asthma and 546 controls at age 8 years using a cross-sectional case-control design. After identification 
of differentially methylated CpG sites in the discovery analysis, we did a validation study in children (4–16 years; 
247 cases and 2949 controls) from six additional European cohorts and meta-analysed the results. We next investigated 
whether replicated CpG sites in cord blood predict later asthma in 1316 children. We subsequently investigated cell-
type-specific methylation of the identified CpG sites in eosinophils and respiratory epithelial cells and their related 
gene-expression signatures. We studied cell-type specificity of the asthma association of the replicated CpG sites in 
455 respiratory epithelial cell samples, collected by nasal brushing of 16-year-old children as well as in DNA isolated 
from blood eosinophils (16 with asthma, eight controls [age 2–56 years]) and compared this with whole-blood DNA 
samples of 74 individuals with asthma and 93 controls (age 1–79 years). Whole-blood transcriptional profiles associated 
with replicated CpG sites were annotated using RNA-seq data of subsets of peripheral blood mononuclear cells sorted 
by fluorescence-activated cell sorting.
Findings 27 methylated CpG sites were identified in the discovery analysis. 14 of these CpG sites were replicated and 
passed genome-wide significance (p<1·14 × 10–⁷) after meta-analysis. Consistently lower methylation levels were 
observed at all associated loci across childhood from age 4 to 16 years in participants with asthma, but not in cord 
blood at birth. All 14 CpG sites were significantly associated with asthma in the second replication study using whole-
blood DNA, and were strongly associated with asthma in purified eosinophils. Whole-blood transcriptional signatures 
associated with these CpG sites indicated increased activation of eosinophils, effector and memory CD8 T cells and 
natural killer cells, and reduced number of naive T cells. Five of the 14 CpG sites were associated with asthma in 
respiratory epithelial cells, indicating cross-tissue epigenetic effects.
Interpretation Reduced whole-blood DNA methylation at 14 CpG sites acquired after birth was strongly associated 
with childhood asthma. These CpG sites and their associated transcriptional profiles indicate activation of eosinophils 
and cytotoxic T cells in childhood asthma. Our findings merit further investigations of the role of epigenetics in a 
clinical context.
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Introduction
Asthma is a heterogeneous chronic inflammatory airway 
disease, characterised by variable respiratory symptoms 
and reversible airflow limitation. Worldwide, more than 
300 million people have asthma, with substantial 
morbidity, reduced quality of life (of patients and their 
families), and substantial health-care costs.1 Asthma 
originates predominantly in early childhood.2 According 
to twin studies, about 50–60% of asthma susceptibility is 
explained by genetic factors.3 Large-scale genome-wide 
association studies (GWAS) have uncovered several 
genetic variants related to asthma, some of which are 
specific to childhood-onset asthma.4,5 The dramatic 
increase in asthma prevalence in the past half-century 
Articles
380 www.thelancet.com/respiratory   Vol 6   May 2018
suggests an important role for early life environmental 
exposures,6,7 which can affect epigenetic patterns, leading 
to changes in gene regulation and, consequently, to 
altered biological responses contributing to disease 
susceptibility.8,9 In support of this, epigenetic changes 
have been observed at specific genomic loci for asthma, 
including DNA methylation CpG sites,10–15 non-coding 
RNAs,16 and microRNA.17 Specifically, previous candidate 
and epigenome-wide studies in peripheral whole blood 
(or peripheral blood mononuclear cells) have found 
methylation associations with immune-related genes 
involved in T-cell regulation and maturation, such as 
FOXP318 and RUNX3.12 Eosinophil-associated genes have 
also been implicated, including IL5RA19 and IL13;12 IL13 
is also differentially methylated in airway epithelial cells 
after stimulation.15 Studies on total immunoglobulin E 
(IgE) levels have also highlighted pathways relevant to 
eosinophil activation10 and lipid or fatty acid metabolism,20 
with suggested involvement in asthma pathogenesis.
Despite recent progress in asthma epigenetics, several 
issues—including which DNA methylation sites are 
robustly associated with asthma across the genome, 
whether these asthma-associated methylation patterns are 
already present at birth or develop during childhood,9 and 
whether age-specific patterns can be observed in children 
from different countries with varying environmental 
exposures and lifestyles—remain largely unresolved. To 
answer these questions, we did a large-scale epigenome-
wide association study (EWAS) of whole-blood DNA in 
children at preschool age (4–5 years) and school age 
(8 years) in four birth cohorts within the Mechanisms of 
the Development of ALLergy (MeDALL) project21, together 
with a validation and replication study in children 
(0–16 years) and adults (18–79 years). We subsequently 
investigated cell-type-specific methy lation of the identified 
CpG sites in eosinophils and respiratory epithelial cells 
and their related gene-expression signatures.
Methods
Study design and participants
Whole-blood DNA from children from four MeDALL 
birth cohorts—BAMSE (Barn/Children, Allergy, Milieu, 
Stockholm, Epidemiology; Sweden),22 EDEN (Etude des 
Determinants pre et post natals du developpement et de la 
sante de l’Enfant; France),23 INMA (Infancia y Medio 
Ambiente–Sabadel [SAB]; Spain),24 and PIAMA 
(Prevention and Incidence of Asthma and Mite Allergy; 
the Netherlands)25—was investigated in the discovery 
analysis.26
All blood DNA samples from children not participating 
in the discovery phase were selected for the replication 
phase from seven MeDALL birth cohorts: BIB (UK), ECA 
(Norway), Karelia (Finland), PIAMA, RHEA (Greece), 
ROBBIC (Italy; subsets Bologna and Rome), and INMA 
(Spain; subsets Gipuzkoa [GIP], Menorca [MEN] and 
Valencia [VAL]; appendix pp 18 –19, 306–07). All of these 
cohorts, apart from Karelia, were included in the main 
meta-analysis.
We defined asthma as described previously in the 
MeDALL study,26 requiring two of three criteria present: 
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Research in context
Evidence before this study
We searched for articles in PubMed published in English up to 
Oct 17, 2017, with the search terms “epigenetics”, “asthma”, 
and “children”, and selected key candidate and epigenome-wide 
studies to be reviewed in more detail. We also searched for 
relevant references in review articles from experts in the field. 
We found evidence that epigenetic changes, including DNA 
methylation CpG sites, non-coding RNAs, and microRNAs had 
been associated with asthma in previous studies. However, it was 
largely unknown which DNA methylation sites were robustly 
associated with asthma across the genome and whether 
age-specific patterns can be observed in children from different 
countries with varying environmental exposures and lifestyles.
Added value of this study
To our knowledge, this is the largest epigenetics study on 
asthma to date, using data from more than 5000 children in 
ten cohorts. By applying stringent genome-wide significance 
criteria (p<1·14 × 10–⁷), our study identified reduced DNA 
methylation levels in 14 CpG sites to be associated with asthma 
across childhood from ages 4 to 16 years, but not at birth. 
Asthma associated whole blood DNA methylation profiles was 
strongly driven by lower methylation within eosinophils 
(average 18% difference in methylation levels in those with 
asthma vs those without), highlighting the importance of the 
eosinophil as an epigenetic determinant of asthma in 
childhood. Through clustering of the 14 asthma-associated 
CpG sites with whole blood and immune-cell-specific gene 
expression signatures, we were also able to annotate the 
asthma-associated CpG sites to activated immune cell subsets 
(CD8-positive T cells and natural killer cells).
Implications of all the available evidence
There is now accumulating evidence that methylation status in 
peripheral blood cells, as well as in disease-relevant tissues such 
as airway epithelial cells, is altered in patients with asthma and 
other respiratory diseases. Our study unequivocally shows that 
reduced whole-blood DNA methylation at specific CpG sites 
acquired after birth is strongly associated with childhood 
asthma. These CpG sites and their associated transcriptional 
profiles indicate activation of eosinophils and cytotoxic T cells. 
Although we were not able to assess causal links between 
methylation status and asthma development in our study, it is 
reasonable to believe that, by targeting methylation status of 
identified genes (ie, normalising levels), asthma-related disease 
activity may be regulated. These observations, together with 
evidence presented before our study, merit further 
investigation of the role of epigenetics in a clinical context.
Articles
www.thelancet.com/respiratory   Vol 6   May 2018 381
doctor diagnosis of asthma ever; use of asthma medication 
in the past 12 months; or wheezing or breathing 
difficulties in the past 12 months.
Medical Ethics Committees of all institutions approved 
this study. Written informed consent was obtained from 
parents or legal guardians of all participating children. A 
full description of the methods is provided in the 
appendix.
Procedures
Given the strong effects of age on whole-blood methylation 
patterns in childhood,9 we considered the possibility of 
age-specific methylation in asthma and performed a 
discovery analysis at age 4–5 years and age 8 years. We 
examined epigenome-wide DNA methylation using 
Illumina Infinium Human Methylation 450 BeadChips 
(450K) in 207 children with asthma and 610 controls at age 
4–5 years, and 185 children with asthma and 546 controls 
at age 8 years using a cross-sectional case-control design 
(figure 1).
We used an independent technology, iPlex (Agena 
Biosciences), to validate and replicate the selected CpG 
sites after quality control of the assays. The most 
significant CpG sites at both age 4–5 years and 8 years 
were selected for replication (appendix pp 20–22). Next 
we investigated whether replicated CpG sites in cord 
blood predict later asthma in 1316 children participating 
in BIB, EDEN, INMA-VAL, and ROBBIC (appendix p 23).
We studied cell-type specificity of the asthma 
association of the replicated CpG sites in 455 respiratory 
epithelial cell samples, collected by nasal brushing of 455 
16-year-old children, as well as in DNA isolated from 
blood eosinophils (16 cases with asthma, eight controls 
[age 2–56 years]) and compared this with whole-blood 
DNA samples of 167 individuals (age 1–79 years) from 
families from the Saguenay-Lac-Saint-Jean (SLSJ) region 
in Canada (appendix p 23).27
The association of CpG methylation with single 
nucleotide polymorphisms (SNPs) was studied in 
496 children, and with matched regional whole-blood 
gene-expression in 119 children (age 4 years, INMA), and 
260 children (age 16 years, BAMSE) using Affymetrix 
Human Transcriptome Array 2.0 Genechips.28 Association 
between CpG methylation and whole-genome expression 
by RNA-seq was assessed in the BIOS consortium dataset.29 
CpG sites were annotated by GREAT (Genomic Regions 
Enrichment of Annotations Tool) version 2.0.2.30 Functional 
enrichment analysis was done by overlapping our 
replicated CpG sites with histone marks and chromatin 
states of 27 blood cell types in the Roadmap epigenome 
project.31 Gene expression sets associated with replicated 
CpG sites were interrogated for cell-type specificity using 
the 500FG dataset.32
Statistical analyses
Asthma-associated differentially methylated CpG sites 
were identified by fitting a robust linear regression 
method corrected for sex, cohort, and technical 
covariables. We used models that do not correct for 
blood cell type as the main model for discovery and 
replication, and report cell-type-corrected models by 
inclusion of the estimated cell type proportions as 
covariates in the sensitivity analysis.
We did inverse variance-weighted fixed-effects 
meta-analyses with METAL,33 or random-effects meta-
analysis using Metafor34 package with statistical 
software environment R in case of a heterogeneity 
χ² test p value less than 0·05. Our replicated 
CpG sites were those that were significantly asso-
ciated in the meta-analysis of replication samples 
(Bonferroni correction, p<0·0019, 27 tests) and passed 
epigenome-wide significance using Bonferroni 
correction (p<1·14 × 10–⁷, 439 306 tests) after meta-
analysis of all studies.
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Figure 1: Study design
The EWAS study consisted of a discovery and replication phase, followed by a 
meta-analysis. The discovery phase was a case-control design with epigenome-
wide DNA methylation in whole-blood DNA measured by Illumina 450K.  The 
top significant CpG sites from the discovery phase were selected for replication 
using the iPlex design in asthma cases and controls from six additional European 
cohorts (n=3196). Finally, results from the discovery and replication phases were 
meta-analysed.
Discovery cohorts n=1548
Cord blood methylation predicting early childhood asthma (EDEN [n=146], 
INMA [n=496,] BIB [n=296], ROBBIC [n=378])
Extra replication (nasel epithelial [n=455], eosinophils [n=24], whole blood 
with full age range [n=167, 1–79 years])
Functional genomics and gene expression (BAMSE [n=260], INMA [n=119], 
BIOS [n=2367])
Gene set and functional enrichment analyses
Genetic association and causality (blood, n=496)
DNA methylation data (Illumina Infinium 450K)
27 candidate CpG sites
Replication cohorts n=3196
DNA methylation data (Agena iPlex)
14 replicated CpG sites
EDEN
4 years
BAMSE
4 years and 
8 years
PIAMA
4–8 years
INMA
4 years
INMABIB RHEA ECA PIAMA KareliaROBBIC
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Role of the funding source
The funders of the study had no role in the design of the 
study, data gathering, analysis, interpretation, writing of 
the report, or in the decision to submit the report for 
publication. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
At age 4–5 years, we identified one genome-wide 
significant CpG site (cg07019303) annotated to ETV6 and 
BCL2L14 (p=7·96 × 10–⁸; appendix pp 20, 308). Therefore, 
we used a looser threshold (false discovery rate [FDR]-
adjusted p<0·10) to select 11 CpG sites for replication 
(appendix p 20) as we considered age-specific effects on 
asthma. We identified 26 CpG sites that passed the 
genome-wide significance threshold (p<1·14 × 10–⁷) at age 
8 years (figure 2B, appendix pp 21–22, 308), with the 
strongest association (p=8·82 × 10–¹⁰) found for 
cg03695871 in AP5B1, a gene associated with eczema.35 
Cg11456013 and cg1362844 were identified at both ages 
4–5 years and 8 years, and 35 CpG sites were selected for 
replication.
IPlex assays for 27 out of the 35 CpG sites selected were 
available after quality control. 3196 samples from six birth 
cohorts were selected for our main meta-analysis. 14 of the 
27 CpG sites were significantly associated with asthma 
across childhood after meta-analysis of the six MeDALL 
replication cohorts and passed the genome-wide signifi-
cance threshold in the meta-analysis of replication and 
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Figure 2: Manhattan plots from the epigenome-wide association studies performed in four European birth cohorts of childhood asthma (discovery)
439 306 CpG sites were tested for association with childhood asthma. The red dotted horizontal line represents the Bonferroni-corrected threshold (p<1·14 × 10–⁷) of 
genome-wide significance. All 14 replicated CpG sites are marked in green dot and annotated with CpG site name. (A) Results for the EWAS analysis in children aged 
4–5 years (n=817) from the four European cohorts BAMSE, EDEN, INMA and PIAMA. (B) Results for the EWAS meta-analysis in children aged 8 years (n=731) from 
BAMSE and PIAMA.
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discovery cohorts (table 1, figure 2A, appendix pp 24–29). 
The expression and function of genes annotated to 
replicated CpG sites are described in the appendix (pp 
30–35), as are the genomic annotations of all CpG sites 
and regional co-methylation plots (appendix pp 309–30). 
The most significant association (p=2·55 × 10–¹⁷) was 
observed for cg01901579 in DICER1 (appendix p 331). 
Specific replication at age 4 years is provided in the 
appendix (p 36), but could not be done at age 8 years due 
to low power. Stratification of asthma cases at age 4 years 
by the presence of specific IgE levels to aeroallergens 
showed association of both specific IgE-positive and 
IgE-negative asthma with the top 11 CpG sites (from the 
4-year discovery analyses), with, on average, stronger 
results for specific IgE-positive asthma (appendix 
pp 37–38). Methylation levels in patients with asthma 
were consistently lower than those in controls for all 
14 replicated CpG sites, with small effects in whole blood 
in the discovery cohorts (appendix pp 332–35). To evaluate 
potential SNP effects within the probe for the 14 replicated 
CpG sites, the β value distributions were visually assessed 
in the discovery cohorts (appendix p 336), and no bimodal 
distribution was detected that could reveal an underlying 
SNP effect within the probe. Additionally, the residuals 
were normally distributed. Homogeneity testing showed 
consistent effects across childhood (4–16 years) for all 
replicated sites (pheterogeneity>0·05; I² <25%; appendix 
pp 337–365). Strikingly, all 14 CpG sites were significantly 
associated with asthma in a second replication study using 
whole-blood DNA from Canadian families (age 1–79 years; 
table 2). However, methylation of the 14 asthma-associated 
CpG sites in 1316 cord-blood DNA samples did not 
significantly predict asthma development at age 3–4 years 
in four different cohorts (appendix p 39).
In our discovery samples, white blood cell composition 
was measured in the INMA cohort (appendix p 40) and 
estimated in all four cohorts (appendix p 40). Asthma was 
significantly associated with lower estimated CD4-positive 
and CD8-positive T-cell subsets in whole blood, but not 
with blood eosinophil counts. However, the association of 
CpG methylation with asthma became less significant 
after eosinophil and neutrophil correction (p values after 
correction ranged from 1·23 × 10–² to 4·41 × 10–⁶ vs 
1·17 × 10–⁶ to 2·79 × 10–⁹ before correction; table 1, appendix 
pp 24–29). Using Reinius’ blood-cell-type specific 
methylation data,36 we found that 11 of the 14 asthma-
associated CpG sites had relatively lower methylation 
levels in eosinophils compared with other blood cell types 
(p=1·92 × 10–²⁴, Fisher’s exact test; appendix pp 41–42).
In the SLSJ cohort, we found all 14 CpG sites within 
eosinophils to be significantly associated with asthma in 
individuals with a very broad age range of 2–56 years 
(appendix p 23). CpG methylation in eosinophils was on 
average 18% lower in participants with asthma (table 2, 
appendix pp 366–79). Furthermore, we found significant 
differential methylation in relation to asthma for five of 
14 CpG sites in nasal respiratory epithelial cells13 from 
children aged 16 years (penrichment=3·8 × 10–⁴; table 2).
Four of 14 CpG sites were associated with SNPs 
within 250 kb (cis-MeQTL; appendix p 43), including 
Age group Chromosome Base pair 
position*
Gene name† Discovery 
coefficient
Discovery 
p value
Eosinophils-
corrected 
p value‡
Houseman 
corrected 
p value§
Replication 
coefficient
Replication 
p value
Meta-
analysis 
coefficient
Meta-
analysis 
p value
cg01445399 4–5 years 1 87 596 934 LOC339524 –0·0120 2·15 × 10–⁶ 4·49 × 10–³ 3·30 × 10–⁵ –0·0156 3·01 × 10–⁵ –0·0129 4·01 × 10–¹⁰
cg01770400 4–5 years 1 173 886 485 SERPINC1 –0·0080 1·17 × 10–⁶ 2·52 × 10–⁴ 2·92 × 10–⁶ –0·0094 1·70 × 10–⁸ –0·0087 1·15 × 10–¹³
cg16592897 4–5 years 1 111 023 201 PROK1, KCNA10 –0·0070 2·35 × 10–⁶ 9·91 × 10–⁴ 6·75 × 10–⁶ –0·0053 2·37 × 10–⁴ –0·0062 3·68 × 10–⁹
cg15344640 4–5 years 5 176 774 729 MXD3, LMAN2 –0·0090 4·77 × 10–⁷ 7·74 × 10–⁴ 1·04 × 10–⁵ –0·0105 1·93 × 10–⁴ –0·0095 4·09 × 10–¹⁰
cg11456013¶ 4–5 years 6 111 192 760 AMD1 –0·0130 2·03 × 10–⁶ 1·23 × 10–² 4·93 × 10–⁵ –0·0141 3·37 × 10–¹¹ –0·0135 3·79 × 10–¹⁶
cg13628444 4–5 years 9 134 883 788 RAPGEF1, 
MED27
–0·0110 1·60 × 10–⁶ 2·96 × 10–³ 4·40 × 10–⁵ –0·0115 5·71 × 10–⁵ –0·0111 3·85 × 10–¹⁰
cg19764973 4–5 years 11 59 525 433 STX3, MRPL16 –0·0090 1·56 × 10–⁶ 8·70 × 10–⁴ 1·74 × 10–⁵ –0·0136 5·16 × 10–¹⁰ –0·0112 1·14 × 10–¹⁴
cg08085199 4–5 years 16 69 170 548 CHTF8, CIRH1A –0.0120 3·94 × 10–⁷ 1·23 × 10–³ 2·85 × 10–⁵ –0·0111 2·84 × 10–⁷ –0·0117 5·79 × 10–¹³
cg10142874  8 years 2 11 917 623 TRIB2, LPIN1 –0·0158 9·42 × 10–⁸ 9·89 × 10–⁴ 2·05 × 10–⁶ –0·0181 1·64 × 10–⁶ –0·0167 1·20 × 10–¹²
cg11456013¶  8 years 6 111 192 760 AMD1 –0·0181 1·15 × 10–⁸ 3·28 × 10–⁴ 9·67 × 10–⁷ –0·0124 1·81 × 10–⁷ –0·0144 4·00 × 10–¹⁴
cg14011077  8 years 9 138 362 327 PPP1R26, 
OLFM1
–0·0154 3·12 × 10–⁸ 8·60 × 10–⁴ 2·76 × 10–⁷ –0·0138 6·02 × 10–⁵ –0·0148 1·06 × 10–¹¹
cg13835688  8 years 9 130 859 454 SLC25A25, 
PTGES2
–0·0212 4·18 × 10–⁸ 4·41 × 10–⁶ 5·64 × 10–⁸ –0·0193 3·95 × 10–⁴ –0·0205 9·01 × 10–¹¹
cg03131767  8 years 12 123 446 272 VPS37B, ABCB9 –0·0159 2·79 × 10–⁹ 2·51 × 10–⁴ 2·49 × 10–⁷ –0·0134 2·08 × 10–⁵ –0·0148 4·48 × 10–¹³
cg01901579  8 years 14 95 615 731 DICER1, CLMN –0·0177 9·52 × 10–⁸ 5·64 × 10–⁵ 1·03 × 10–⁶ –0·0188 5·58 × 10–¹¹ –0·0183 2·55 × 10–¹⁷
cg06483820  8 years 17 55 167 149 MSI2, AKAP1 –0·0159 1·63 × 10–⁸ 2·65 × 10–⁴ 1·27 × 10–⁶ –0·0119 2·20 × 10–⁵ –0·0139 2·30 × 10–¹²
*Base pair position according to Genome build 37. †The CpG sites were annotated by GREAT version 2.0.2. ‡Eosinophils-corrected p value: p value from discovery study after correct estimated cell counts, 
including eosinophils (CD8 and CD4 T cells, natural killer cells, B cells, monocytes, eosinophils, neutrophils). §Houseman corrected p value: p value from discovery study after correct estimated cell counts with 
default Houseman setting (CD8 and CD4 T cells, natural killer cells, B cells, monocytes, granulocytes). ¶The same CpG sites were detected in both age groups.  
Table 1: Description of 14 unique replicated asthma CpG sites across childhood
See Online for appendix
For more on GREAT (Genomic 
Regions of Annotations Tool 
see http://bejerano.stanford.
edu/great/
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rs9425436, which was associated with CpG methylation 
of cg01770400 in SERPINC1 (p=5·6 × 10–⁴). rs9425436 was 
in strong linkage disequilibrium (r²=0·95) with rs4652298 
in ZBTB37, which has previously been shown to be 
associated with asthma (p=2·7 × 10–³) in the GABRIEL 
GWAS.4 Mediation analysis revealed that 14·4% of the 
SNP rs9425436 effect on asthma was due to CpG 
methylation of cg01770400 (appendix p 43). 13 of 
14 replicated CpG sites were significantly enriched for 
enhancer markers in whole-blood Roadmap and Encode 
data31 (appendix pp 44–45).
Four asthma-associated CpG sites were significantly 
associated with gene expression in cis in BAMSE 
(appendix p 46), but this was not replicated in the smaller 
INMA dataset (appendix p 47). In the larger BIOS 
dataset,29 which contains participants from the Dutch 
LifeLines Deep study,37 Leiden Longevity Study,38 and the 
Netherlands Twin register,39 we analysed the association 
of the 14 CpG sites with gene expression in cis in 
2367 adults, and identified ten of the 14 asthma-associated 
CpG sites to be associated with 22 gene transcripts 
(appendix p 48), with two CpG-gene transcript pairs 
(cg06483830-SCPEP1 and cg14011077-PPP1R26) also 
observed in the BAMSE dataset (appendix p 46).
All CpG sites showed significant associations with 
whole-blood gene expression (mean number of 
associated transcripts 351 [SD 228]). All associated 
transcripts are shown per CpG site in the appendix 
(pp 49–238). We identified three distinct gene expression 
patterns in whole blood by hierarchical clustering. The 
first cluster was inversely associated with methylation 
levels of seven CpG sites, and included genes such as 
SLC29A1, SIGLEC8, IL5RA, and ADORA3 (figure 3A, 
appendix pp 49–238). A second cluster was strongly 
associated with cg16592897 and six other CpG sites, and 
included genes such as CCR7, CHMP7, and LEF1. After 
correction for eosinophil blood counts, association of the 
first cluster was attenuated, confirming this as an 
eosinophilic gene signature, whereas the association of 
the second cluster became more prominent. In contrast, 
the third cluster, containing TBX21, EOMES, CCL5, and 
GZMB, showed negative correlation with four asthma 
CpG methylation levels (figure 3B, appendix pp 239–305). 
An RNA-seq dataset of peripheral blood mononuclear 
cells fluorescence-activated cell-sorted into highly 
defined leucocyte subsets32 identified the second cluster 
as a naive CD4 and CD8 T cell gene signature that was 
decreased, and the third cluster as an effector and 
memory CD8 T cell and natural killer cell profile that 
was increased with reduced CpG methylation 
(appendix pp 380–82).
Discussion
This large consortium-based meta-analysis identified 
14 CpG sites in whole blood to be associated with childhood 
asthma. Consistently lower methylation of these CpG sites 
was observed in individuals with asthma from age 
4–5 years until adolescence. Strongly reduced methylation 
at asthma-associated CpG sites within isolated eosinophils 
clearly indicated that lower whole-blood DNA methylation 
levels in asthma were due not only to altered eosinophil 
numbers in whole blood, but also to reduced methylation 
at those specific CpG sites in this cell type. Finally, through 
clustering of the 14 asthma associated CpG sites with 
whole-blood and immune-cell-specific gene expression 
signatures, we were able to annotate the asthma-associated 
Gene name Whole blood 
coefficient*
Whole blood 
p value†
Eosinophils 
coefficient‡
Eosinophils 
p value§
Nasal epithelial 
coefficient¶
Nasal epithelial 
p value||
cg01901579 DICER1, CLMN –0·0188 1·44 × 10–⁶ –0·180 0·0030 –0·0112 0·0008
cg13628444 RAPGEF1, MED27 –0·0152 5·08 × 10–⁵ –0·225 0·0009 –0·0159 0·0037
cg19764973 STX3, MRPL16 –0·0072 0·0001 –0·264 0·0228 –0·0113 0·0052
cg01445399 LOC339524 –0·0153 0·0005 –0·212 0·0191 –0·0124 0·0148
cg13835688 SLC25A25, PTGES2 –0·0159 7·94 × 10–⁵ –0·216 0·0004 –0·0120 0·0190
cg11456013  AMD1 –0·0147 0·0004 –0·189 0·0023 –0·0069 0·2074
cg15344640 MXD3, LMAN2 –0·0089 0·0009 –0·236 0·0038 –0·0035 0·3413
cg01770400 SERPINC1 –0·0050 0·0111 –0·140 0·0017 –0·0032 0·3610
cg06483820 MSI2, AKAP1 –0·0107 0·0060 –0·185 0·0064 0·0046 0·4942
cg03131767 VPS37B, ABCB9 –0·0106 0·0117 –0·215 0·0037 –0·0045 0·6359
cg10142874 TRIB2, LPIN1 –0·0201 1·16 × 10–⁵ –0·191 0·0006 –0·0019 0·6745
cg08085199 CHTF8, CIRH1A –0·0148 0·0014 –0·229 0·0092 0·0027 0·7121
cg16592897 PROK1, KCNA10 –0·0066 0·0223 –0·070 0·0021 –0·0004 0·9072
cg14011077  PPP1R26, OLFM1 –0·0123 0·0205 –0·108 0·0050 –0·0010 0·9099
*Regression coefficient from association study of SLSJ whole blood. †p value from association study of SLSJ whole blood. ‡Regression coefficient from association study of 
SLSJ isolated eosinophils. §p value from association study of SLSJ isolated eosinophils. ¶Regression coefficient from association study of PIAMA nasal epithelial cells. ||p value 
from association study of PIAMA nasal epithelial cells.
Table 2: Association of the 14 replicated CpG sites with asthma in whole-blood samples from SLSJ (n=167), eosinophil cells from SLSJ (n=24), and nasal 
epithelial cells from PIAMA (n=455)
Articles
www.thelancet.com/respiratory   Vol 6   May 2018 385
CpG sites to (activated) eosinophils and CD8-positive 
T cells and natural killer cells.
DNA methylation can be strongly affected by ageing and 
environmental exposures.8,9 We observed remarkably 
consistent patterns of DNA methylation associated with 
childhood asthma across different age groups and in 
participants from different countries. This suggests that 
our asthma-associated CpG sites are consistent findings in 
childhood asthma from the age of 4 years onwards, but we 
did not find this association at birth, indicating postnatal 
effects on methylation of the 14 CpG sites identified in our 
study. Recently, cord-blood methylation of a CpG site in 
another asthma gene, SMAD3, was found to be associated 
with childhood asthma in children of mothers with 
asthma.11 Maternal smoking during pregnancy, a risk 
factor for childhood asthma, showed strong effects on 
methylation of 6073 CpG sites in DNA isolated from cord 
blood.8 One of these CpG sites was associated with asthma 
in our study (LMAN2), but we did not identify a mediating 
effect of smoking on asthma through this CpG (data not 
shown). Thus, asthma-associated DNA methylation 
patterns identified in this study are likely to be the result of 
postnatal environmental influences, pathophysiological 
processes related to asthma, or both. We performed 
detailed functional analysis of the asthma-associated CpG 
sites to start identifying these processes.
Part of the reduced DNA methylation of the 14 CpG 
sites in asthma was explained by eosinophil numbers, 
Figure 3: Heatmap and hierarchical clustering of z-scores of the genes most significantly associated with methylation levels of the 14 CpG sites
(A) Selection of the top 99 associated genes using BIOS data from 2367 individuals. The heatmap was plotted on z-scores from the meta-analysis of three cohorts (Lifelines Deep, Leiden Longevity Study, 
and Netherlands Twin Register). (B) Selection of the top 99 genes after correction for eosinophil counts in the model. The heatmap was plotted on z-scores from meta-analysis of the same three cohorts.
A Heatmap of Z score of overlapped genes (without Eos correction)
B Heatmap of Z score of overlapped genes (with Eos correction)
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since the significance of the association was reduced 
after correction for predicted eosinophil percentage in 
peripheral blood.20 Importantly, strongly reduced 
methylation of the CpG sites in purified eosinophils 
retained an association with asthma, highlighting that 
eosinophils are epigenetically altered in asthma. We 
observed a larger effect size in purified eosinophils (on 
average 18% lower in individuals with asthma than in 
those without asthma) compared with whole blood (on 
average 1–2% lower in individuals with asthma than in 
those without asthma), consistent with a functional effect 
on gene expression in eosinophils. As predicted, 
eosinophil counts were not significantly different 
between patients with asthma and controls in our 
discovery cohorts, suggesting that our results reflect the 
presence of a different subset or activation state of 
eosinophils, rather than a change in eosinophil counts 
per se. Although eosinophils are linked to sub-
phenotypes of asthma such as the T helper 2-type 
subset,40  our study provides unequivocal data supporting 
their involvement at the epigenetic level in mild-to-
moderate asthma in children. This adds to the genetic 
findings41 that SNPs regulating blood eosinophil counts 
significantly overlap with asthma GWAS loci, such as 
IL5, IL33, IL1RL1, and TSLP. Functional interpretation 
using Roadmap epigenomics data revealed that asthma-
associated CpG sites were significantly enriched for 
enhancer markers, again suggesting a cell-type-specific 
regulatory role in gene expression.42
Correlation of our 14 CpG sites with genome-wide gene 
expression revealed three clusters of associated genes. 
Because all replicated 14 CpG sites show consistently 
reduced DNA methylation in patients with asthma, the 
cluster encompassing known eosinophil signature 
genes43 that are negatively associated with methylation 
levels of asthma-associated CpG sites is therefore 
predicted to show increased expression in asthma. 
A second cluster with increased predicted expression in 
asthma is characterised by effector and memory CD8 
T cell and natural killer cell genes. A third cluster with 
reduced predicted expression in asthma was identified as 
naive CD4 and CD8 T cells. These data indicate that 
whole-blood DNA from children with asthma carries 
CpG methylation marks associated with reduced activity 
of naive T cells and increased activity of effector and 
memory CD8 T cells and natural killer cells.44 This 
asthma-associated shift in cellular activity might be due 
to different environmental factors such as traffic-related 
air pollution or infectious agents, including intracellular 
bacteria or viruses.45 Further studies are needed in well 
characterised populations of children with asthma to 
address cell-type-specific methylation signatures together 
with RNA-seq data in effector memory CD8-positive 
T cells and natural killer cells to disentangle a cell 
proportion effect from differential cell activation in 
asthma. Thus, asthma-associated whole-blood methyl-
ation patterns represent an epigenetic fingerprint of 
(activated) immune cell subsets acquired in childhood. 
Given that large methylation differences were seen in 
eosinophils from individuals with asthma compared 
with those without asthma, we believe that our findings 
could have a direct clinical impact in the future by aiding 
diagnostics, guiding drug discovery programmes, or 
both. For example, rapid tests for eosinophil methylation 
status available for clinical use could be a valuable 
diagnostic tool to identify children with asthma, and we 
encourage such new research efforts. Although we are 
not able to assess causal links between methylation 
status and asthma development in our study, it is 
reasonable to believe that, by targeting the methylation 
status of identified genes (ie, normalising levels), asthma-
related disease activity might be regulated.
Comparing the 14 CpG sites with a DNA methylation 
study of asthma in US inner cities,12 we did not identify 
overlapping CpG sites. However, three of the genome-
wide significant CpG sites (cg01770400, cg20503329, 
cg09447105; appendix pp 20–22) were previously reported 
in an EWAS for total IgE,10 compatible with shared 
regulation of these CpG sites in asthma and IgE-related 
traits. None of these annotated genes was previously 
implicated in (genetic) studies of asthma (see appendix, 
pp 30–35, for an overview); however, several of these 
genes (DICER1, STX3, LIPIN1) have known functions 
that might be relevant to asthma development. The most 
significant CpG site was annotated to DICER1 (appendix 
p 331). DICER1 is a member of the ribonuclease III 
family, involved in the generation of microRNAs, which 
modulate gene expression at the post-transcriptional 
level. SYNTAXIN3 (STX3) is relevant for epithelial 
polarity and regulates exocytosis.46 Epithelial polarity is 
important to maintain epithelial barrier function, a 
process that is impaired in asthma.47 STX3 plays an 
important part in the release of chemokines CXCL8, 
CCL2, CCL3, and CCL4 by human mast cells.48 LIPIN1 is 
a Mg²+-dependent phosphatidic acid phosphohydrolase, 
which has been shown to negatively regulate mast cell 
degranulation and the anaphylactic response through 
inhibiting the PKC–SNAP-23 pathway.49 LIPIN1 also has 
a role in macrophage proinflammatory activation 
during Toll-like receptor (TLR) signalling. After TLR4 
stimulation, Lipin-1-deficient macrophages showed a 
decreased production of diacylglycerol and activation of 
MAP kinases and AP-1, accompanied by a reduced 
production of proinflammatory cytokines such as IL-6, 
IL-12, and IL-23, or enzymes such as inducible nitric 
oxide synthase.50 
Finally, LMAN2 (lectin, mannose binding 2) encodes a 
type I transmembrane lectin that shuttles between the 
endoplasmic reticulum, the Golgi apparatus, and the 
plasma membrane, and has previously been implicated 
in sphingolipid transport.51
Our study has some strengths and some limitations. To 
our knowledge, this is the first study to combine EWAS 
with an extensive validation and replication study of CpG 
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sites using an independent laboratory method in more 
than 5000 children. One limitation of our work is that we 
used a questionnaire-based approach to define asthma at 
age 4–5 years based on doctor’s diagnosis, symptoms, and 
use of asthma medication. Although we acknowledge that 
self-reported asthma at age 4–5 years could be sensitive to 
misclassification of transient wheezing, our finding that 
eight of the 11 CpG sites selected from the age 4–5 years 
discovery sample were significantly associated with 
asthma throughout childhood strongly suggests that we 
found robust asthma CpG sites. However, we cannot 
ignore that the challenges of diagnosing asthma in young 
children might partly explain why we identified only one 
genome-wide CpG site in the initial EWAS discovery on 
4–5-year olds. Since we a priori considered age-specific 
effects on DNA methylation in asthma, two sets of CpG 
sites were selected for replication at age 4–5 years and 
8 years. Although different significance cutoffs were used 
for this initial selection (FDR <0·1 at age 4–5 years, 
Bonferroni significance at age 8 years), this did not affect 
the final outcome because all CpG sites passed robust 
criteria for replication (Bonferroni significance in the 
replication analysis, as well as in the final combined 
meta-analysis of discovery and replication studies). 
Additionally, replication analyses of our 14 top hits in the 
SLSJ cohort allowed us not only to assess methylation 
profiles in purified eosinophils, but also to show that 
hypomethylation of these CpG sites was observed in 
participants with asthma at a broader age range (age 
1–79 years). A second limitation is that the CpG selection 
was limited to the 450K platform that, by design, only 
covers 1·6% of all methylation sites of the genome. We 
would expect to find many more asthma-associated CpG 
sites using whole-methylome sequencing in the future. 
Third, we can address CpG loci but not CpG regions in 
our study since CpG regions cannot be replicated in the 
targeted iPlex design. Fourth, small differences in 
methylation levels between cases and controls were 
observed in the whole-blood samples, whereas substantial 
differences were seen in purified eosinophils. This 
indicates dilution of the strong methylation effects (in 
eosinophils) if whole blood is used for analyses. Finally, 
we observed replication of five of the 14 CpG sites in 
respiratory nasal epithelial cells, but cannot exclude the 
possibility that (part of) this signal is due to admixture of 
eosinophils in epithelial brushings.
In conclusion, our study identified consistently reduced 
DNA methylation levels in 14 CpG sites to be associated 
with asthma across childhood from ages 4 to 16 years, but 
not at birth. Asthma-associated whole-blood DNA 
methylation profiles were strongly driven by lower 
methylation within eosinophils, highlighting the 
importance of eosinophils as an epigenetic determinant 
of asthma. Additionally, CpG methylation patterns 
identified an early-life shift from naive T cell populations 
towards effector and memory CD8 and natural killer cell 
subsets, indicating a potentially crucial role for host–
virus interactions in asthma inception. Our study reveals 
whole-blood methylation signatures that represent an 
epigenetic fingerprint of (activated) eosinophil and 
CD8-positive T cell and natural killer cell subsets 
acquired in childhood.
Contributors
GHK and EM conceived the project and coordinated the analyses. 
CJX analysed epigenome-wide data for discovery and replication. 
GHK, EM, CJX, CS and MCN drafted the manuscript. MCN contributed to 
the biological interpretation. CS, OG, SKM, AK, GP, DG, LR, JK, and EM 
provided the biological materials and phenotype information of BAMSE. 
MBu, MBa, SL, MT, SG, JGA, CI, JRB, and JS provided the biological 
materials and phenotype information of INMA. NB and IAM provided the 
biological materials and phenotype information of EDEN. UG, JCdJ, HAS, 
and BB provided the biological materials and phenotype information of 
PIAMA. DM, RRCM, RA, and JW provided the biological materials and 
phenotype information of BIB. LC and MK provided the biological 
materials and phenotype information of Rhea. FF, MPF, DG, and DP 
provided the biological materials and phenotype information of ROBBIC. 
KCL, VH, PM, and KHC provided the biological materials and phenotype 
information of ECA. TH, HA, NF, and TL provided the biological materials 
and phenotype information of Karelia. OG implemented the shadow 
analysis of EWAS. CL designed, recruited, evaluated, and managed the 
SLSJ study. AM, MFM, WOCMC, and CL implemented and coordinated 
replication in SLSJ. MK constructed the MeDALL asthma phenotypes. 
SKM did eQTM analysis of BAMSE 16 years. CJX did eQTM analysis of 
BIOS data. MJB contributed Great and Roadmap data annotation. RAG, 
YL, CW, and MGN implemented and coordinated RNA seq analysis in 
500G. CJV did PIAMA RNA seq analysis. SB, NL, JP, and CA 
implemented and coordinated eQTM analysis in INMA. BvR, SAJ, PvDV, 
CCvD, and CS designed and produced the 450k and iplex data. JMA and JB 
coordinated the MeDALL project. All authors were involved in data 
interpretation, and read and approved the manuscript.
Declaration of interests
JP reports grants from the European Commission, during the conduct of 
the study. JB reports personal fees from Almirall, AstraZeneca, Chiesi, 
GSK, Meda, Menarini, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, 
Teva, and Uriach, outside of the submitted work. MCN reports grants 
from EU FP7 program - MeDALL project, during the conduct of the 
study; and grants from GSK Ltd and personal fees from DC4U, outside 
of the submitted work. CL reports a pending patent named “Refractory 
asthmatics with high levels of IgE and low levels of methylation”. 
EM reports grants from the EU (ERC) during conduct of the study, and 
lecture fees from Thermo Fisher Scientific and Meda outside of the 
submitted work. GHK reports grants from the EU and grants from Lung 
Foundation of the Netherlands, during the conduct of the study; and 
grants from TETRI foundation, grants from UBBO EMMIUS 
foundation, and grants from TEVA the Netherlands, outside of the 
submitted work. All other authors declare no competing interests.
Acknowledgments
We are grateful to all children and families who participated in this 
study. We especially thank Professsor Dirkje Postma for helpful 
comments and support during the course of this study. The Mechanisms 
of the Development of ALLergy (MeDALL) EU project was supported by 
the seventh Framework programme (grant agreement number 261357). 
The Biobank-Based Integrative Omics Studies (BIOS) Consortium is 
funded by BBMRI-NL, a research infrastructure financed by the Dutch 
government (NWO 184.021.007). ISGlobal is a member of the CERCA 
Programme, Generalitat de Catalunya.
References
1 Eder W, Ege MJ, von Mutius E. The asthma epidemic. 
N Engl J Med 2006; 355: 2226–35.
2 Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, 
Morgan WJ. Asthma and wheezing in the first six years of life. 
N Engl J Med 1995; 332: 133–38.
3 McGeachie MJ, Stahl EA, Himes BE, et al. Polygenic heritability 
estimates in pharmacogenetics: focus on asthma and related 
phenotypes. Pharmacogenet Genomics 2013; 23: 324–28.
Articles
388 www.thelancet.com/respiratory   Vol 6   May 2018
4 Moffatt MF, Gut IG, Demenais F, et al. A large-scale, 
consortium-based genomewide association study of asthma. 
N Engl J Med 2010; 363: 1211–21.
5 Ober C, Nicolae DL. Meta-analysis of genome-wide association 
studies of asthma in ethnically diverse North American 
populations. Nat Genet 2011; 43: 887–92.
6 Stein MM, Hrusch CL, Gozdz J, et al. Innate immunity and asthma 
risk in Amish and Hutterite farm children. N Engl J Med 2016; 
375: 411–21.
7 Ege MJ, Mayer M, Normand A-C, et al. Exposure to environmental 
microorganisms and childhood asthma. N Engl J Med 2011; 
364: 701–09.
8 Joubert BR, Felix JF, Yousefi P, et al. DNA methylation in newborns 
and maternal smoking in pregnancy: genome-wide consortium 
meta-analysis. Am J Hum Genet 2016; 98: 680–96.
9 Xu C-J, Bonder MJ, Söderhäll C, et al. The emerging landscape of 
dynamic DNA methylation in early childhood. BMC Genomics 2017; 
18: 25.
10 Liang L, Willis-Owen SAG, Laprise C, et al. An epigenome-wide 
association study of total serum immunoglobulin E concentration. 
Nature 2015; 520: 670–74.
11 DeVries A, Wlasiuk G, Miller SJ, et al. Epigenome-wide analysis links 
SMAD3 methylation at birth to asthma in children of asthmatic 
mothers. J Allergy Clin Immunol 2017; 140: 534–42.
12 Yang IV, Pedersen BS, Liu A, et al. DNA methylation and childhood 
asthma in the inner city. J Allergy Clin Immunol 2015; 136: 69–80.
13 Yang IV, Richards A, Davidson EJ, et al. The nasal methylome: 
a key to understanding allergic asthma. Am J Respir Crit Care Med 
2017; 195: 829–31.
14 Nicodemus-Johnson J, Myers RA, Sakabe NJ, et al. DNA 
methylation in lung cells is associated with asthma endotypes and 
genetic risk. JCI Insight 2016; 1: e90151.
15 Nicodemus-Johnson J, Naughton KA, Sudi J, et al. Genome-wide 
methylation study identifies an IL-13–induced epigenetic signature 
in asthmatic airways. Am J Respir Crit Care Med 2016; 193: 376–85.
16 Austin PJ, Tsitsiou E, Boardman C, et al. Transcriptional profiling 
identifies the long noncoding RNA plasmacytoma variant translocation 
(PVT1) as a novel regulator of the asthmatic phenotype in human 
airway smooth muscle. J Allergy Clin Immunol 2017; 139: 780–89.
17 Maes T, Cobos FA, Schleich F, et al. Asthma inflammatory 
phenotypes show differential microRNA expression in sputum. 
J Allergy Clin Immunol 2016; 137: 1433–46.
18 Nadeau K, McDonald-Hyman C, Noth EM, et al. Ambient air 
pollution impairs regulatory T-cell function in asthma. 
J Allergy Clin Immunol 2010; 126: 845–852.e10.
19 Arathimos R, Suderman M, Sharp GC, et al. Epigenome-wide 
association study of asthma and wheeze in childhood and 
adolescence. Clin Epigenetics 2017; 9: 112.
20 Chen W, Wang T, Pino-Yanes M, et al. An epigenome-wide 
association study of total serum IgE in Hispanic children. 
J Allergy Clin Immunol 2017; 140: 571–77. 
21 Bousquet J, Anto J, Auffray C, et al. MeDALL (Mechanisms of the 
Development of ALLergy): an integrated approach from phenotypes 
to systems medicine. Allergy 2011; 66: 596–604.
22 Ballardini N, Bergström A, Wahlgren C-F, et al. IgE antibodies in 
relation to prevalence and multimorbidity of eczema, asthma, and 
rhinitis from birth to adolescence. Allergy 2016; 71: 342–49.
23 Baïz N, Slama R, Béné M-C, et al. Maternal exposure to air 
pollution before and during pregnancy related to changes in 
newborn’s cord blood lymphocyte subpopulations. The EDEN study 
cohort. BMC Pregnancy Childbirth 2011; 11: 1–12.
24 Guxens M, Ballester F, Espada M, et al. Cohort Profile: The 
INMA—INfancia y Medio Ambiente—(Environment and 
Childhood) Project. Int J Epidemiol 2012; 41: 930–40.
25 Wijga AH, Kerkhof M, Gehring U, et al. Cohort profile: 
The Prevention and Incidence of Asthma and Mite Allergy 
(PIAMA) birth cohort. Int J Epidemiol 2014; 43: 527–35.
26 Pinart M, Benet M, Annesi-Maesano I , et al. Comorbidity of 
eczema, rhinitis, and asthma in IgE-sensitised and 
non-IgE-sensitised children in MeDALL: a population-based cohort 
study. Lancet Respir Med 2014; 2: 131–40.
27 Laprise C. The Saguenay-Lac-Saint-Jean asthma familial collection: 
the genetics of asthma in a young founder population. 
Genes Immun 2014; 15: 247–55.
28 Gref A, Merid SK, Gruzieva O, et al. Genome-wide interaction 
analysis of air pollution exposure and childhood asthma with 
functional follow-up. Am J Respir Crit Care Med 2017; 195: 1373–83.
29 Bonder MJ, Luijk R, Zhernakova DV, et al. Disease variants alter 
transcription factor levels and methylation of their binding sites. 
Nat Genet 2017; 49: 131–38.
30 McLean CY, Bristor D, Hiller M, et al. GREAT improves functional 
interpretation of cis-regulatory regions. Nat Biotechnol 2010; 
28: 495–501.
31 Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A. 
Integrative analysis of 111 reference human epigenomes. 
Nature 2015; 518: 317–30.
32 Aguirre-Gamboa R, Joosten I, Urbano PCM, et al. Differential 
effects of environmental and genetic factors on T and B cell 
immune traits. Cell Rep 2016; 17: 2474–87.
33 Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis 
of genomewide association scans. Bioinformatics 2010; 26: 2190–91. 
34 Viechtbauer W. Conducting meta-analyses in R with the metafor 
package. J Stat Softw 2010; 36: i03.
35 Paternoster L, Standl M, Chen C-M, et al. Meta-analysis of 
genome-wide association studies identifies three new risk loci for 
atopic dermatitis. Nat Genet 2012; 44: 187–92.
36 Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlen SE, Greco D. 
Differential DNA methylation in purified human blood cells: 
implications for cell lineage and studies on disease susceptibility. 
PLoS One 2012; 7: e41361.
37 Tigchelaar EF, et al. Cohort profile: LifeLines DEEP, a prospective, 
general population cohort study in the northern Netherlands: study 
design and baseline characteristics. BMJ Open 2015; 5: e006772 
(2015). 
38 Schoenmaker M, et al. Evidence of genetic enrichment for 
exceptional survival using a family approach: the Leiden Longevity 
Study. Eur J Hum Genet 2006; 14: 79–84.
39 Willemsen G, et al. The Adult Netherlands Twin Register: 
twenty-five years of survey and biological data collection. 
Twin Res Hum Genet 2013; 16: 271–81.
40 George L, Brightling CE. Eosinophilic airway inflammation: role in 
asthma and chronic obstructive pulmonary disease. 
Ther Adv Chronic Dis 2016; 7: 34–51.
41 Astle WJ, Elding H, Jiang T, et al. The Allelic landscape of human 
blood cell trait variation and links to common complex disease. 
Cell 2016; 167: 1415–1429.e19.
42 Heinz S, Romanoski CE, Benner C, Glass CK. The selection and 
function of cell type-specific enhancers. Nat Rev Mol Cell Biol 2015; 
16: 144–54.
43 Choy DF, Jia G, Abbas AR, et al. Peripheral blood gene expression 
predicts clinical benefit from anti-IL-13 in asthma. 
J Allergy Clin Immunol; 138: 1230–1233.e8.
44 Abdelsamed HA, Moustaki A, Fan Y, et al. Human memory CD8 T 
cell effector potential is epigenetically preserved during in vivo 
homeostasis. J Exp Med 2017; 214: 1593.
45 Youngblood B, Hale JS, Ahmed R. Memory CD8 T cell 
transcriptional plasticity. F1000Prime Rep 2015; 7: 38.
46 Vogel GF, Klee KMC, Janecke AR, Müller T, Hess MW, Huber LA. 
Cargo-selective apical exocytosis in epithelial cells is conducted by 
Myo5B, Slp4a, Vamp7, and Syntaxin 3. J Cell Biol 2015; 211: 587.
47 Davies DE. Epithelial barrier function and immunity in asthma. 
Ann Am Thorac Soc 2014; 11: S244–51.
48 Frank SPC, Thon K-P, Bischoff SC, Lorentz A. SNAP-23 and 
syntaxin-3 are required for chemokine release by mature human 
mast cells. Mol Immunol 2011; 49: 353–58.
49 Shin J, Zhang P, Wang S, Wu J, Guan Z, Zhong X-P. 
Negative control of mast cell degranulation and the anaphylactic 
response by the phosphatase lipin1: Innate immunity. 
Eur J Immunol 2013; 43: 240–48.
50 Meana C, Peña L, Lordén G, et al. Lipin-1 Integrates lipid synthesis 
with proinflammatory responses during TLR activation in 
macrophages. J Immunol 2014; 193: 4614–22.
51 Levy BD. Sphingolipids and susceptibility to asthma. 
N Engl J Med 2013; 369: 976–78.
